Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor | Universidade de São Paulo (USP) | - |
Autor(es): dc.contributor | Universidade Estadual Paulista (Unesp) | - |
Autor(es): dc.contributor | Faculdade de Medicina de Ribeirão Preto | - |
Autor(es): dc.creator | Viani, Gustavo A. | - |
Autor(es): dc.creator | Arruda, Caio V. [UNESP] | - |
Autor(es): dc.creator | De Fendi, Ligia I. | - |
Data de aceite: dc.date.accessioned | 2022-02-22T00:26:47Z | - |
Data de disponibilização: dc.date.available | 2022-02-22T00:26:47Z | - |
Data de envio: dc.date.issued | 2020-12-11 | - |
Data de envio: dc.date.issued | 2020-12-11 | - |
Data de envio: dc.date.issued | 2020-08-01 | - |
Fonte completa do material: dc.identifier | http://dx.doi.org/10.1097/COC.0000000000000709 | - |
Fonte completa do material: dc.identifier | http://hdl.handle.net/11449/199226 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/11449/199226 | - |
Descrição: dc.description | OBJECTIVE: The effectiveness and safety of reirradiation with stereotactic ablative radiotherapy (re-SABR) in patients with recurrence after a previous course of radiation are limited to small series. We carried out a meta-analysis to summarize existing data and identify trends in overall survival (OS), local control (LC), and toxicity after re-SABR in patients with recurrence of lung cancer. MATERIALS AND METHODS: Eligible studies were identified on Medline, Embase, the Cochrane Library, and the proceedings of annual meetings through June 2019. We followed the PRISMA and MOOSE guidelines. A meta-regression analysis was carried out to assess whether there is a relationship between moderator variables and outcomes. A P-value<0.05 was considered significant. RESULTS: Twenty observational studies with a total of 595 patients treated were included. The 2-year OS and LC were 0.54 (95% confidence interval [CI]: 0.48-0.61) and 0.73 (95% CI: 0.66-0.80), respectively. The rate of any toxicity grade ≥3 was 0.098 (95% CI: 0.06-13.6), with 9 grade 5 toxicity (1.5%). In the meta-regression, the re-SABR dose (P=0.028), tumor size (P=0.031), and time to recurrence (P=0.018) showed an association with survival. For LC, the re-SABR dose (P=0.034) and tumor size (P=0.040) were statistically significant. Any toxicity grade ≥3 showed a relationship with the cumulative dose (P=0.024). Cumulative dose ≤145 versus >145 Gy2 had 3% versus 15% (P=0.013) of any grade ≥3 toxicity. CONCLUSIONS: Re-SABR produces satisfactory LC and OS rates with an acceptable rate of toxicity. The balancing between the re-SABR dose and the tumor location has the potential to reduce severe and fatal toxicity. | - |
Descrição: dc.description | Ribeirão Preto Medical School University of São Paulo | - |
Descrição: dc.description | Bioscience Institute of University of State from Sao Paulo (UNESP) | - |
Descrição: dc.description | Faculdade de Medicina de Ribeirão Preto | - |
Descrição: dc.description | Bioscience Institute of University of State from Sao Paulo (UNESP) | - |
Formato: dc.format | 575-581 | - |
Idioma: dc.language | en | - |
Relação: dc.relation | American journal of clinical oncology | - |
???dc.source???: dc.source | Scopus | - |
Título: dc.title | Effectiveness and Safety of Reirradiation With Stereotactic Ablative Radiotherapy of Lung Cancer After a First Course of Thoracic Radiation: A Meta-analysis | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional - Unesp |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: